At two months after injection, we found that knockdown of S100a9 expression had improved the cognition decline of Tg2576 mice in the water maze task, and had reduced amyloid plaque burden.
Patients with low SIRT3 expression had improved five-year colon cancer-specific survival and overall survival compared to patients with high SIRT3 expression determined by the IRS score.
Patients with ER-positive tumors with a high tumoral CXCR3 expression had improved effect of tamoxifen when compared with patients with ER-positive tumors and low CXCR3 expression.
Patients with combinations of high HIF-1 α and CAIX expression or high CAIX and GLUT1 expression had improved 5-year LRFS with RT+CON (61% and 47%, respectively) compared with RT alone (16% and 18%, respectively, P=0.01 and 0.03).
Patients with high HIF-1 α expression had improved 5-year local relapse-free survival with RT+CON (47%) compared with RT alone (21% hazard ratio (HR) 0.48, 95% CI 0.26 0.8, P=0.02), no benefit was seen with low HIF-1 α expression (HR 0.81, 95% CI 0.43 1.50, P=0.5).
Availability: http://cebc.unc.edu/software/ Contact: [email protected]; [email protected] The computational pipeline for gene expression studies has improved in recent years with a degree of consensus surrounding pre-processing and normalization, analysis of differential expression and biological interpretation of the findings (Allison et al., 2006).
Gene expression profiling has improved the understanding of molecular subtypes of breast cancer.
The quality of gene expression microarray data has improved dramatically since the first arrays were introduced in the late 1990s.
Profiling global gene expression in breast cancer has improved our understanding of the clinical diversity of this disease, allowing a better classification of its subtypes and definition of their response to drug treatment.
Gene expression profiling using microarray technologies has improved our understanding of breast cancer biology and has led to the development of a breast cancer molecular taxonomy and of multigene 'signatures' to predict outcome and response to systemic therapies.
